APTO vs. ALGS, DYAI, INAB, CRIS, ACHL, CYTH, QNCX, INKT, PLUR, and NKGN
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Aligos Therapeutics (ALGS), Dyadic International (DYAI), IN8bio (INAB), Curis (CRIS), Achilles Therapeutics (ACHL), Cyclo Therapeutics (CYTH), Quince Therapeutics (QNCX), MiNK Therapeutics (INKT), Pluri (PLUR), and NKGen Biotech (NKGN). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences (NASDAQ:APTO) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
Aptose Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -783.72%. Aligos Therapeutics' return on equity of -144.16% beat Aptose Biosciences' return on equity.
Aptose Biosciences has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
26.6% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 4.6% of Aptose Biosciences shares are owned by insiders. Comparatively, 16.5% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Aptose Biosciences received 354 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. Likewise, 64.89% of users gave Aptose Biosciences an outperform vote while only 62.16% of users gave Aligos Therapeutics an outperform vote.
Aptose Biosciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.
Aptose Biosciences currently has a consensus target price of $14.83, indicating a potential upside of 2,511.50%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Aligos Therapeutics.
In the previous week, Aptose Biosciences had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for Aptose Biosciences and 3 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.88 beat Aptose Biosciences' score of 0.58 indicating that Aligos Therapeutics is being referred to more favorably in the news media.
Summary
Aptose Biosciences and Aligos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
